Know Cancer

forgot password

A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B

18 Years
Open (Enrolling)
Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer

Thank you

Trial Information

A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B


I. Estimate the rate of clinical benefit (objective response plus stable disease) for
patients treated with 28-day cycles of vorinostat (first 5 consecutive days each week for
day 1-21) concurrent with daily aromatase inhibitor (AI) therapy (all 28 days).


I. Assess the safety and tolerability of vorinostat and AI combination therapy in patients
with metastatic breast cancer.

II. Assess the change in estrogen receptor (ER) expression, measured as the change in F-18
16 alpha-fluoroestradiol (FES) standardized uptake value (SUV) using FES positron emission
tomography (PET) completed per protocol 7184 after two weeks of vorinostat and AI therapy
and after 8 weeks of therapy.

III. Assess tumor metabolic response, measured as the change in fludeoxyglucose F 18 (FDG)
SUV using FDG PET completed per protocol 7184 after two weeks of vorinostat and AI therapy
and after 8 weeks of therapy.

IV. Assess the change in hormone levels (estradiol, estrone, follicle-stimulating hormone
[FSH], sex binding globulin, testosterone, and free testosterone) after 8 weeks of therapy.

V. Assess the change in ER, progesterone receptor (PR), human epidermal growth factor
receptor 2 (HER2), androgen receptor (AR), epidermal growth factor receptor (EGFR), vascular
endothelial growth factor (VEGF) tumor expression after two weeks of vorinostat and AI
therapy in patients that consent to optional tissue biopsy procedure.

VI. Assess the time to progression and the overall survival of patients treated with 28-day
cycles of vorinostat (first 5 consecutive days each week for day 1-21) concurrent with daily
AI therapy (all 28 days).


Patients receive vorinostat orally (PO) 5 days a week for 3 weeks. Patients also receive AI
therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily
for 4 weeks. Courses repeat every 28 days in the absence of disease progression and
unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years,
then every 6 months until progression, and then annually thereafter.

Inclusion Criteria:

- Histologically or cytologically proven diagnosis of breast cancer

- Stage IV disease

- Patient has previously derived clinical benefit from endocrine therapy, but is no
longer deriving benefit to endocrine therapy in the opinion of the treating

- At least one site of measurable disease, as defined by the modified Response
Evaluation Criteria in Solid Tumors (RECIST) criteria

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Female patient is post menopausal as defined by one of the following; free from
menses for >= 2 years, surgically sterilized, FSH and estradiol in post-menopausal
range AND surgical absence of uterus OR chemotherapy induced amenorrhea lasting > 1
year OR currently on ovarian suppression

- Female patient of childbearing potential has a negative urine or serum (beta human
chorionic gonadotropin [B-hCG]) pregnancy test within 14 days prior to receiving the
first dose of vorinostat

- Male patient agrees to use two barrier methods of contraception or abstain from
intercourse for the duration of the study

- Absolute neutrophil count (ANC) >= 1,500/mcL

- Platelets >= 100,000/mcL

- Hemoglobin >= 9 g/dL

- Prothrombin time or international normalized ratio (INR) =< 1.5 x upper limit of
normal (ULN) unless receiving therapeutic anticoagulation

- Partial thromboplastin time (PTT) =< 1.2 times the ULN unless the patient is
receiving therapeutic anticoagulation

- Potassium (K) levels normal limits

- Magnesium (Mg) levels normal limits

- Calculated creatinine clearance >= 30 mL/min

- Creatinine clearance should be calculated per institutional standard

- Serum total bilirubin =< 1.5 x ULN

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x

- Alkaline phosphatase =< 2.5 x ULN

- Patient, or the patient's legal representative, has voluntarily agreed to participate
by giving written informed consent

- Patient has a life expectancy of at least 12 weeks in the opinion of the treating

- Patient is willing to continue on same AI therapy

- Patient agrees to participate in imaging protocol 7184 and is separately consented

Exclusion Criteria:

- Patient has not derived clinical benefit from prior endocrine therapy

- Patient is currently participating or has participated in a study with an
investigational compound or device within 30 days of initial dosing with study
drug(s) other than the imaging protocol 7184

- Patient has received an ER blocking therapy (selective estrogen receptor modulating
or downregulating selective estrogen receptor modulator [SERM] or selective estrogen
receptor degrader [SERD] i.e. tamoxifen or fulvestrant) within the past 6 weeks

- Patient had prior treatment with an histone deacetylase (HDAC) inhibitor (e.g.,
romidepsin [Depsipeptide], NSC-630176, MS 275, LAQ-824, belinostat (PXD-101), LBH589,
MGCD0103, CRA024781, etc); patients who have received compounds with HDAC
inhibitor-like activity, such as valproic acid, as anti-tumor therapy should not
enroll in this study; patients who have received such compounds for other
indications, e.g. valproic acid for epilepsy, may enroll after a 30-day washout

- Patient is on any systemic steroids that have not been stabilized to the equivalent
of =< 10 mg/day prednisone during the 30 days prior to the start of the study drugs

- Patient has known hypersensitivity to the components of study drug or its analogs

- Patients with uncontrolled brain metastases

- New York Heart Association (NYHA) class III or IV congestive heart failure,
myocardial infarction within the previous 6 months, QTc > 0.47 seconds, or
uncontrolled arrhythmia

- Type I diabetes mellitus; patients with type II diabetes mellitus will be included as
long as their glucose can be controlled to under 200 mg/dL

- Patient is pregnant or breast feeding, or expecting to conceive or father children
within the projected duration of the study

- Patient with a "currently active" second malignancy, other than non-melanoma skin
cancer and carcinoma in situ of the cervix, should not be enrolled; patients are not
considered to have a "currently active" malignancy if they have completed therapy for
a prior malignancy, are disease free from prior malignancies for > 5 years or are
considered by their physician to be at less than 30% risk of relapse

- Patients with known active viral hepatitis

- Patient has a history or current evidence of any condition, therapy, or laboratory
(lab) abnormality that might confound the results of the study, interfere with the
patient's participation for the full duration of the study or is not in the best
interest of the patient to participate

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Rate of clinical benefit of patients receiving vorinostat/AI combination therapy according to RECIST

Outcome Description:

A 90% score (Wilson) confidence interval will be computed for the rate of clinical benefit.

Outcome Time Frame:

Up to 5 years

Safety Issue:


Principal Investigator

Hannah Linden

Investigator Role:

Principal Investigator

Investigator Affiliation:

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium


United States: Food and Drug Administration

Study ID:




Start Date:

November 2012

Completion Date:

Related Keywords:

  • Male Breast Cancer
  • Recurrent Breast Cancer
  • Stage IV Breast Cancer
  • Breast Neoplasms
  • Breast Neoplasms, Male



Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumSeattle, Washington  98109